Primary vs secondary hypogonadism: Where the problem starts and why it changes everything

Primary and secondary hypogonadism are separated by LH and FSH, not by testosterone alone: high LH and FSH with low testosterone means primary testicular failure, while low or normal LH and FSH with low testosterone means secondary hypogonadism that may respond to Enclomiphene instead of testosterone replacement. At Veedma, persistent symptoms plus morning total testosterone below 350 ng/dL or free testosterone below 100 pg/mL still require gonadotropin testing before treatment is chosen. Getting that distinction wrong can shut down sperm production in a man who might have preserved fertility with a different approach.

Key takeaways

• Male hypogonadism is a clinical syndrome that requires persistent symptoms plus biochemical deficiency, and at Veedma that means interpreting morning testosterone with a practical threshold of 350 ng/dL for total testosterone or 100 pg/mL for free testosterone.
• Primary hypogonadism, also called hypergonadotropic hypogonadism, shows low testosterone with high LH and FSH because the pituitary is already signaling as hard as it can.
• Secondary hypogonadism, also called hypogonadotropic hypogonadism, shows low testosterone with low or inappropriately normal LH and FSH, and at Veedma Enclomiphene is the first-line therapy for secondary and functional hypogonadism when LH is below 8 mIU/mL and the axis appears intact.
• Klinefelter syndrome affects about 1 in 500 to 1,000 male births, yet fewer than 50% of cases are diagnosed during life.
• Functional hypogonadism is the most common real world type of low testosterone and usually reflects reversible suppression from obesity, metabolic syndrome, type 2 diabetes, medications, or systemic illness rather than permanent structural damage.
• TRT suppresses gonadotropins and spermatogenesis, so starting testosterone before classifying the type can compromise fertility.

Why the origin matters more than the number

Two men with the same testosterone result can need opposite treatments because LH and FSH reveal whether the defect is in the testes or in the hypothalamic pituitary signal above them.^{[1] [3]}

Hypogonadism means testosterone production or testosterone action is insufficient for normal male function. According to the Endocrine Society, the diagnosis requires symptoms plus consistently low testosterone, not a single low result in isolation. That point matters here because classification only begins after deficiency is biochemically confirmed.^{[1] [3]}

This is why “types of low testosterone” are not academic labels. Primary hypogonadism usually needs testosterone replacement because the testes cannot respond. Secondary hypogonadism may allow restoration of natural production because the testes are still potentially functional. Functional hypogonadism often sits inside the secondary category, but it is especially important because the axis is suppressed, not destroyed.

At Veedma, classification starts with morning testing between 07:00 and 11:00 and includes total testosterone, free testosterone measured directly by equilibrium dialysis with LC-MS/MS, estradiol, LH, and FSH. Free testosterone is prioritized because a man can have apparently acceptable total testosterone and still have clinically important androgen deficiency if free testosterone is low. Veedma can also analyze existing outside labs, including broad wellness panels such as Function Health, but if LH and FSH are missing the case is still unclassified. That is why treatment without gonadotropins is guesswork.

For the full lab workflow, see the complete low testosterone testing guide and the HPG axis explainer.

Primary hypogonadism and hypergonadotropic hypogonadism

Primary hypogonadism is low testosterone caused by testicular failure, and its laboratory hallmark is high LH and FSH because the pituitary is already pushing hard.^[3]

Hypergonadotropic means the gonadotropins, LH and FSH, are elevated. In plain language, the brain is “screaming,” but the testes cannot answer.

What the labs mean in primary hypogonadism

EMAS investigators showed that this pattern is distinct from secondary hypogonadism because the feedback loop is intact enough to recognize low testosterone, yet the testes fail to produce adequate hormone despite maximal stimulation. Once this pattern is confirmed in a symptomatic man, stimulating the pituitary harder is not a rational treatment strategy. Enclomiphene is therefore not appropriate in true primary hypogonadism.

In practice, this is the group that usually needs TRT for androgen replacement. That does not mean fertility is solved. Quite the opposite. A World Journal of Men’s Health review emphasized that exogenous testosterone suppresses gonadotropins and acts as a contraceptive, so it should never be started casually in a man who may want children.^{[1] [6]}

Common causes of primary hypogonadism

A 2003 Danish registry study found that Klinefelter syndrome, 47,XXY, occurs in roughly 1 in 500 to 1,000 live male births, yet fewer than half of affected men are diagnosed during life.^[4]

Congenital causes of primary hypogonadism include the following:

• Klinefelter syndrome
• Cryptorchidism
• Bilateral anorchia
• Myotonic dystrophy
• Disorders of sex development affecting testicular function
• Sickle cell disease

Acquired causes include the following:

• Chemotherapy, especially alkylating agents
• Testicular irradiation
• Surgical castration or direct testicular trauma
• Orchitis, including mumps orchitis
• Testicular torsion
• Environmental toxic exposure
• Alcohol related testicular injury and cirrhosis associated gonadal damage

The key clinical implication is simple. In primary hypogonadism, the testes are the failing organ. Treatment replaces what the testes cannot make.

Secondary hypogonadism and hypogonadotropic hypogonadism

Secondary hypogonadism is low testosterone caused by weak hypothalamic or pituitary signaling, so LH and FSH are low or inappropriately normal despite low testosterone.^[3]

Hypogonadotropic means gonadotropin output is too low for the degree of testosterone deficiency. In plain language, the testes may still work, but the brain is not telling them to.

Why treatment is different in secondary hypogonadism

Because the testes are potentially intact, secondary hypogonadism is the main setting in which restoring the signal can restore natural testosterone production. Enclomiphene is a selective estrogen receptor modulator that blocks estrogen feedback at the hypothalamus, increasing GnRH and then LH and FSH, which stimulates the testes to produce testosterone naturally. It preserves spermatogenesis, maintains testicular size and function, and works with the body’s own regulation rather than shutting the axis down.^[6]

At Veedma, Enclomiphene is the first line therapy for secondary and functional hypogonadism when LH is below 8 mIU/mL and the axis appears intact. Gonadotropin therapy with hCG and FSH is another option, especially when fertility is the immediate priority, but for men who do not need immediate fertility preservation Enclomiphene is often the preferred alternative because it is simpler and keeps the axis active. Testosterone cypionate is reserved for men who fail stimulation therapy or who are later shown to have a nonresponsive axis.

Common causes of secondary hypogonadism

According to endocrine guidelines, the common causes of secondary hypogonadism fall into drug induced, localized, and systemic groups, and reviews of hypogonadism in obesity and metabolic disease identify obesity, metabolic syndrome, and type 2 diabetes as common functional or secondary contributors.^{[1] [8]}

• Drug induced causes include opiates, exogenous testosterone or anabolic steroids, GnRH agonists or antagonists, glucocorticoids, and estrogens.
• Localized causes include pituitary tumors, traumatic brain injury, pituitary surgery, pituitary irradiation, and hyperprolactinemia.
• Systemic causes include obesity, type 2 diabetes, metabolic syndrome, chronic organ failure, eating disorders, endurance overtraining, and acute illness.

This category is the most common in day to day practice. It is also the category most often mismanaged when clinics prescribe TRT before checking LH and FSH.

Functional hypogonadism and reversible HPG suppression

Functional hypogonadism is the most common real world form of testosterone deficiency and reflects a suppressed but structurally intact HPG axis rather than permanent gland damage.^{[5] [8]}

Functional means there is no recognized organic lesion in the hypothalamus, pituitary, or testes. HPG axis means the brain to testes signaling pathway that controls testosterone production.

This pattern is driven mainly by comorbidities. In obesity and metabolic disease, inflammatory cytokines, adipocytokines, and increased estradiol production from adipose tissue suppress the axis. The result is low testosterone with an intact system that has been turned down, not destroyed.

In a 2013 systematic review and meta analysis, weight loss improved obesity associated hypogonadotropic hypogonadism, but the average hormonal rise was modest. That is why lifestyle advice alone often leaves symptomatic men untreated for too long.^[5]

This is the ideal setting for Enclomiphene plus lifestyle modification. The medication can “wake up” the axis by blocking estrogen mediated suppression while the underlying driver is addressed. At Veedma, this is where individualized plans matter most. Men with intact signaling patterns undergo a thorough workup, often with more than 40 biomarkers checked twice per year, and treatment is adjusted over time rather than defaulting immediately to lifelong TRT. For a deeper discussion of reversibility, see functional vs organic hypogonadism.

Androgen resistance and decreased bioactivity

Androgen resistance is a third category of androgen deficiency in which testosterone may be present, sometimes even in the normal range, but tissues cannot use it effectively.^{[7] [9]}

Bioactivity means how much testosterone actually reaches and activates its receptor in tissues.

This group is often missed because the problem is not only production. Congenital causes include androgen insensitivity, 5 alpha reductase deficiency, Kennedy disease, and androgen receptor CAG repeat variation. Acquired causes include finasteride or dutasteride use, spironolactone and other antiandrogens, elevated SHBG states that reduce free testosterone availability, and coeliac disease.

A Lancet review on androgen insensitivity and classic androgen receptor literature make the central point clearly: the clinical effect of testosterone depends on receptor response, not only on serum concentration. That is one reason Veedma prioritizes direct free testosterone measurement by equilibrium dialysis with LC-MS/MS. Normal total testosterone does not always mean normal androgen action.

Compensated or subclinical hypogonadism

Compensated hypogonadism is defined by normal testosterone with elevated LH, showing that the pituitary is working harder to keep testosterone in range.^[3]

Subclinical means the biochemical strain appears before clear hormone failure has fully developed.

EMAS investigators described this as a warning pattern rather than a settled diagnosis with a clear treatment algorithm. The clinical significance remains uncertain, but it may represent early or evolving hypogonadism. In practical terms, it is not reassuring enough to ignore and not specific enough to treat automatically.

The correct response is monitoring. Repeat morning total testosterone, direct free testosterone, LH, and FSH, and track whether symptoms emerge or worsen. A man with compensated hypogonadism may later declare himself as overt primary hypogonadism if testosterone falls while LH stays high, or as a different phenotype if the hormone pattern changes.

How age of onset changes presentation

Age of onset changes the phenotype of hypogonadism, so the same hormonal defect can look like a developmental disorder in one patient and like “normal aging” in another.^{[1] [2]}

Fetal onset

When androgen deficiency or androgen resistance begins during fetal development, the presentation can range from severe undervirilization to major virilization defects, including female appearing external genitalia in the most severe receptor disorders.^{[7] [9]}

Pre or peri pubertal onset

When onset occurs before or during puberty, delayed puberty and eunuchoid body proportions become the dominant clues. The diagnosis is often more obvious because testosterone is needed for pubertal progression, body composition, and skeletal maturation.

Post pubertal or adult onset

In adult onset disease, including late onset hypogonadism, symptoms are usually milder and are often confused with the aging process. A 2010 New England Journal of Medicine study helped define this group by showing that adult hypogonadism must still be anchored in symptoms plus biochemical deficiency, not vague complaints alone. This is why adult cases are commonly missed, especially when clinicians focus on age instead of the hormone pattern and the source of failure.

Myth vs fact

Myth: One testosterone number tells you the treatment

Fact: The treatment hinges on LH and FSH. High LH with low testosterone points to primary hypogonadism and usually TRT, while low or normal LH with low testosterone points to secondary hypogonadism and may make Enclomiphene the better first step.^{[1] [3]}

Myth: TRT is the universal starting point for all types of low testosterone

Fact: TRT is appropriate for documented hypogonadism when replacement is needed, but it suppresses gonadotropins and spermatogenesis, so using it before classification can unnecessarily compromise fertility in men with secondary or functional hypogonadism.^{[1] [6]}

Myth: Secondary hypogonadism always means permanent brain disease

Fact: The most common clinical pattern is functional suppression from obesity, metabolic syndrome, type 2 diabetes, medications, or systemic illness, and these men often have an intact axis that can respond to Enclomiphene and treatment of the underlying condition.^{[5] [8]}

Myth: Normal total testosterone rules out an androgen problem

Fact: Normal total testosterone does not rule out low free testosterone or impaired androgen action. Compensated hypogonadism is a warning phenotype with normal testosterone and elevated LH that warrants repeat evaluation rather than automatic classification as confirmed androgen deficiency.^{[3] [7] [9]}

Bottom line

Primary versus secondary hypogonadism tells you whether the failure starts in the testes or in the signaling centers above them, and that distinction determines whether a man needs testosterone replacement or may preserve fertility with Enclomiphene or other stimulation therapy. Functional hypogonadism is the common reversible version of secondary suppression, while androgen resistance and compensated hypogonadism are often missed because testosterone production is not the whole story. For the full diagnostic and treatment roadmap, see the Low Testosterone hub.

References

1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. 2018;103:1715-1744. PMID: 29562364
2. Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. The New England journal of medicine. 2010;363:123-35. PMID: 20554979
3. Tajar A, Forti G, O’Neill TW, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. The Journal of clinical endocrinology and metabolism. 2010;95:1810-8. PMID: 20173018
4. Bojesen A, Juul S, Gravholt CH. Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. The Journal of clinical endocrinology and metabolism. 2003;88:622-6. PMID: 12574191
5. Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. European journal of endocrinology. 2013;168:829-43. PMID: 23482592
6. Patel AS, Leong JY, Ramos L, Ramasamy R. Testosterone Is a Contraceptive and Should Not Be Used in Men Who Desire Fertility. World journal of men’s health. 2019;37:45-54. PMID: 29959444
7. Hughes IA, Davies JD, Bunch TI, et al. Androgen insensitivity syndrome. Lancet (London, England). 2012;380:1419-28. PMID: 22698698
8. Corona G, Vignozzi L, Sforza A, Mannucci E, Maggi M. Obesity and late-onset hypogonadism. Molecular and cellular endocrinology. 2015;418 Pt 2:120-133. PMID: 26208943
9. Quigley CA, De Bellis A, Marschke KB, et al. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocrine reviews. 1995;16:271-321. PMID: 7671849